logo
AAT Bioquest

Screen Quest™ Colorimetric Glucose Uptake Assay Kit

Measurement of 2DG uptake in differentiated 3T3-L1 adipocytes and 3T3-L1 fibroblasts. Assays were performed with Screen Quest™ Colorimetric Glucose Uptake Assay Kit in a black wall/clear bottom cell culture Poly-D lysine plate using a SpectraMax (Molecular Devices) microplate reader. (A: Negative Control, no insulin no 2-DG treatment. B: 2DG uptake in the absence of insulin. C: 2DG uptake in the presence of 1mM insulin. D: 2DG uptake in the presence of 1mM insulin and 200 mM phloretin. E: 2DG uptake in the presence of insulin 1mM and 5mM D-Glucose.) 
Measurement of 2DG uptake in differentiated 3T3-L1 adipocytes and 3T3-L1 fibroblasts. Assays were performed with Screen Quest™ Colorimetric Glucose Uptake Assay Kit in a black wall/clear bottom cell culture Poly-D lysine plate using a SpectraMax (Molecular Devices) microplate reader. (A: Negative Control, no insulin no 2-DG treatment. B: 2DG uptake in the absence of insulin. C: 2DG uptake in the presence of 1mM insulin. D: 2DG uptake in the presence of 1mM insulin and 200 mM phloretin. E: 2DG uptake in the presence of insulin 1mM and 5mM D-Glucose.) 
Measurement of 2DG uptake in differentiated 3T3-L1 adipocytes and 3T3-L1 fibroblasts. Assays were performed with Screen Quest™ Colorimetric Glucose Uptake Assay Kit in a black wall/clear bottom cell culture Poly-D lysine plate using a SpectraMax (Molecular Devices) microplate reader. (A: Negative Control, no insulin no 2-DG treatment. B: 2DG uptake in the absence of insulin. C: 2DG uptake in the presence of 1mM insulin. D: 2DG uptake in the presence of 1mM insulin and 200 mM phloretin. E: 2DG uptake in the presence of insulin 1mM and 5mM D-Glucose.) 
Ordering information
Price
Catalog Number
Unit Size
Quantity
Add to cart
Additional ordering information
Telephone1-800-990-8053
Fax1-800-609-2943
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
ShippingStandard overnight for United States, inquire for international
Request quotation
Storage, safety and handling
H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
UNSPSC12352200
Related products
Screen Quest™ Membrane Potential Assay Kit *Orange Fluorescence*
Screen Quest™ Membrane Potential Assay Kit *Red Fluorescence*
Screen Quest™ 10X cell staining buffer with Phenol Red Plus™
Screen Quest™ 10X calcium assay buffer with Phenol Red Plus™
Screen Quest™ Luminometric Calcium Assay Kit
Screen Quest™ Fluo-8 Medium Removal Calcium Assay Kit *Optimized for Difficult Cell Lines*
Screen Quest™ Fluo-8 No Wash Calcium Assay Kit
Screen Quest™ Fura-2 No Wash Calcium Assay Kit
Screen Quest™ Rhod-4 No Wash Calcium Assay Kit *Medium Removal*
Screen Quest™ Rhod-4 No Wash Calcium Assay Kit
Screen Quest™ Fluorimetric MDR Assay Kit
Screen Quest™ Colorimetric Chloride Channel Assay Kit
Screen Quest™ Colorimetric ELISA cAMP Assay Kit
Screen Quest™ Fluorimetric ELISA cAMP Assay Kit
Screen Quest™ TR-FRET No Wash cAMP Assay Kit
Screen Quest™ Live Cell cAMP Assay Service Pack
Screen Quest™ Fluorimetric Fatty Acid Uptake Assay Kit
Screen Quest™ HEK-CNGC-Amylin 3 Receptor Cells
Screen Quest™ HEK-CNGC-Cannabinoid Receptor 1 Cells
Screen Quest™ CHO-Ga16- Chemokine (C-C) Receptor 2B Cells
Screen Quest™ HEK-CNGC-Chemokine (C-X-C motif) Receptor 4 Cells
Screen Quest™ HEK-CNGC-Dopamine Receptor 1 (DRD1) Cells
Screen Quest™ HEK-CNGC-Glucagon-like Receptor 1 (GLP1R) Cells
Screen Quest™ HEK-CNGC-Opiate Receptor-like 1 (ORL1) Cells
Screen Quest™ Human Nociceptin Receptor Ga16 coupled CHO Cells (NOP-Ga16)
Screen Quest™ CHO-Gqi Chimera Cell line
Screen Quest™ CHO-Gqo Chimera Cell line
Screen Quest™ CHO-Gqz Chimera Cell line
Screen Quest™ CHO-Gqs Chimera Cell line
Screen Quest™ CHO-Ga16 Chimera Cell line
Screen Quest™ Fluo-4 No Wash Calcium Assay Kit
Screen Quest™ No Wash Potassium Channel Assay Kit
Screen Quest™ Calbryte-520 Probenecid-Free and Wash-Free Calcium Assay Kit
Screen Quest™ Calbryte-590 Probenecid-Free and Wash-Free Calcium Assay Kit
Show More (24)

OverviewpdfSDSpdfProtocol


Glucose transport systems are responsible for transporting glucose across cell membranes. Measuring uptake of 2-deoxyglucose (2-DG), a glucose analog, in tissues and cells is widely accepted as a reliable method to estimate the amount of glucose uptake and to investigate the regulation of glucose metabolism and mechanism of insulin resistance. The 2-DG uptake is commonly determined by using non-metabolized 2-DG labeled with tritium or C14. However, routine use of a radiolabelled probe is costly and requires a tedious special handling procedure. AAT Bioquest's Screen Quest™ Colorimetric Glucose Uptake Assay Kit provides a sensitive and non-radioactive assay in tissues or cultured cells. In this assay 2-DG is taken up by glucose transporters, and metabolized to 2-DG-6-phosphate (2-DG6P). The non-metabolizable 2-DG6P accumulates in the cells, and is proportional to glucose uptake by cells. The accumulated 2-DG6P is enzymatically oxidized and generates NADPH, which is specifically monitored by a chromogenic NADPH sensor. The signal can be read by a absorption microplate reader by reading the OD ratio at wavelength 570 nm to 610 nm.

Platform


Absorbance microplate reader

Absorbance570/610 nm
Recommended plateClear bottom

Components


Example protocol


AT A GLANCE

Protocol summary

  1. Plate cells and treat the cells as desired
  2. Add 10 µL/well 2-DG and incubate at 37oC for 20-40 minutes
  3. Wash cells and lyse cells
  4. Add 50 µL/well of 2-DG Uptake Assay working solution
  5. Incubate at RT for 30 to 120 minutes
  6. Monitor OD ratio increase at 570/610 nm

Important notes
Thaw all the kit components at room temperature before starting the experiment. The above mentioned protocol is for one 96-well plate.

PREPARATION OF STOCK SOLUTION

Unless otherwise noted, all unused stock solutions should be divided into single-use aliquots and stored at -20 °C after preparation. Avoid repeated freeze-thaw cycles.

KRPH Buffer stock solution (1X):
Add 20 mL of KRPH Buffer (5X) (Component H) to 80 mL of deionized water and mix them well. Note: 50 mL volume of 1× KRPH Buffer is enough for approximately one 96-well plate. Prepare the needed volume proportionally. Store the unused 1×KRPH at 4oC or -20oC.

PREPARATION OF WORKING SOLUTION

1. NADP working solution:
Add 100 µL of H2O into the vial of NADP (Component G) and mix them well.

2. Enzyme Probe working solution:
Add 5 mL of Assay Buffer (Component F) into the bottle of Enzyme Probe (Component E) and mix them well.

3. 2-DG Uptake Assay working solution:
Add 100 µL of NADP working solution into the Enzyme Probe working solution and mix them well. Note: These quantities are good for one 96-well plate.

SAMPLE EXPERIMENTAL PROTOCOL

Important: This protocol can be used as guidelines to culture 3T3-L1 adipocytes for 2-DG uptake.

  1. Plate cells in growth medium at 50,000-80,000 cells/well/100 µL/96-well or 12,500-20,000 cells/well/25 µL/384-well black wall/clear bottom cell culture Poly-D lysine plate for 4-6 hours before experiment.

  2. Remove the cell plate from the incubator, aspirate the medium from the wells, and deprive the cells with 100 µL/well (96 well-plate) or 25 µL/well (384 well-plate) serum free medium. Incubate the cells at 37oC, 5% CO2 incubator for 6 hours to overnight.

  3. Remove the cell plate from the incubator, aspirate the medium from the wells, and gently wash the cells twice with 100 µL/well 1× KRPH buffer.

  4. Add 90 µL/well Glucose Uptake Buffer (Component B) and incubate the cells at 37oC, 5% CO2 incubator for 1 hour.

  5. Stimulate with or without insulin or compound of test for 20 min. Add 10 µL/well of the 10× insulin solution to a final concentration of 1 µM or 10× compound solution of test. And also add 10 µL insulin vehicle buffer or compound vehicle buffer to the untreated wells as control, and incubate at 37oC, 5% CO2 incubator for 20 mins.

  6. For glucose uptake inhibition study, add 10× Phloretin to a final concentration of 200 uM or inhibitors of test, and incubate at 37oC, 5% CO2 for 2-5 mins. Note: 10 mL inhibitor vehicle buffer is suggested to be added to both the insulin treated and untreated wells as control. Phloretin treated cells can be used as positive control.

  7. Add 10 µL/well 2-DG solution (Component A) to each well, and incubate at 37oC, 5% CO2 incubator for 20-40 mins. For negative controls, leave some wells untreated with insulin, inhibitor and 2-DG.

  8. After treatment, remove solution in each well and gently wash cells 3 times, 100 µL/well with KRPH Buffer to remove the extra 2-DG from the solution. Remove KRPH Buffer from the wells.

  9. Add 25 µL/well Acidic Lysis Buffer (Component C) to each well and incubate at 37oC for 20 min to lyse the cells. And the 2DG uptake assay mixture could be prepared in the meantime.

  10. Add 25 µL/well Neutralization Buffer (Component D) to each well, mix thoroughly, leave at room temperature for 5-10 minutes to neutralize the cell lysate.

  11. Add 50 µL of 2DG Uptake Assay working solution to each well of 2-DG6P standard (Not provided) or cell lysate.

  12. Incubate the reaction at room temperature for 30 minutes to 2 hours, protected from light.

  13. Monitor the absorbance ratio increase at 570/610 nm with an absorbance plate reader.

Images


Citations


View all 11 citations: Citation Explorer
TFAIP6 facilitates hepatocellular carcinoma cell glycolysis through upregulating c-Myc/PKM2 axis
Authors: Duan, Kecai and Fang, Kunpeng and Sui, Chengjun
Journal: Heliyon (2024): e30959
Exosomes from PYCR1 knockdown bone marrow mesenchymal stem inhibits aerobic glycolysis and the growth of bladder cancer cells via regulation of the EGFR/PI3K/AKT pathway
Authors: Li, Zhuo and Jiang, Ying and Liu, Jian and Fu, Huifeng and Yang, Quan and Song, Wei and Li, Yuanwei
Journal: International Journal of Oncology (2023): 1--13
METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression
Authors: Xia, Peng and Zhang, Hao and Lu, Haofeng and Xu, Kequan and Jiang, Xiang and Jiang, Yuke and Gongye, Xiangdong and Chen, Zhang and Liu, Jie and Chen, Xi and others,
Journal: Cancer Communications (2023)
Cancer-associated fibroblast-secreted miR-421 promotes pancreatic cancer by regulating the SIRT3/H3K9Ac/HIF-1$\alpha$ axis
Authors: Zhou, Bin and Lei, Jing-Hao and Wang, Qiang and Qu, Teng-Fei and Cha, Li-Chao and Zhan, Han-Xiang and Liu, Shang-Long and Hu, Xiao and Sun, Chuan-Dong and Guo, Wei-Dong and others,
Journal: The Kaohsiung Journal of Medical Sciences (2022): 1080--1092
lncENST Suppress the Warburg Effect Regulating the Tumor Progress by the Nkx2-5/ErbB2 Axis in Hepatocellular Carcinoma
Authors: Chen, Geng and Jiang, Jiayun and Wang, Xiaofei and Feng, Kai and Ma, Kuansheng
Journal: Computational and Mathematical Methods in Medicine (2021)
Impaired glucocorticoid receptor expression in liver disrupts feeding-induced gene expression, glucose uptake, and glycogen storage
Authors: Pr{\ae}stholm, Stine M and Correia, Catarina M and Goitea, Victor E and Siersb{\ae}k, Majken S and J{\o}rgensen, Mathilde and Havelund, Jesper F and Pedersen, Thomas {\AA} and F{\ae}rgeman, Nils J and Gr{\o}ntved, Lars
Journal: Cell reports (2021): 109938
miR-143-3p functions as a tumor suppressor by targeting HK2 in neuroblastomas
Authors: Cen, Yuanhua and Xu, Li and Huang, Saihu and Zhuang, Songqiang
Journal: Int J Clin Exp Med (2019): 8450--8460
Corticotropin releasing hormone can selectively stimulate glucose uptake in corticotropinoma via glucose transporter 1
Authors: Lu, Jie and Montgomery, Blake K and Chatain, Gr{\'e}goire P and Bugarini, Alejandro and Zhang, Qi and Wang, Xiang and Edwards, Nancy A and Ray-Chaudhury, Abhik and Merrill, Marsha J and Lonser, Russell R and others,
Journal: Molecular and cellular endocrinology (2018): 105--114
Corticotropin releasing hormone can selectively stimulate glucose uptake in corticotropinoma via glucose transporter 1
Authors: Lu, Jie and Montgomery, Blake K and Chatain, Grégoire P and Bugarini, Alej and ro , undefined and Zhang, Qi and Wang, Xiang and Edwards, Nancy A and Ray-Chaudhury, Abhik and Merrill, Marsha J and Lonser, Russell R and others, undefined
Journal: Molecular and Cellular Endocrinology (2017)

References


View all 115 references: Citation Explorer
Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus
Authors: Chen LH, Leung PS.
Journal: Diabetes Obes Metab. (2013)
Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents
Authors: Washburn WN., undefined
Journal: Expert Opin Ther Pat (2012): 483
Regulation of glucose transporter translocation in health and diabetes
Authors: Bogan JS., undefined
Journal: Annu Rev Biochem (2012): 507
New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors
Authors: Simonyi G., undefined
Journal: Orv Hetil (2012): 695
Glucose transporter type I deficiency syndrome: epilepsy phenotypes and outcomes
Authors: Pong AW, Geary BR, Engelstad KM, Natarajan A, Yang H, De Vivo DC.
Journal: Epilepsia (2012): 1503
A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'
Authors: Chan HW, Ashan B, Jayasekera P, Collier A, Ghosh S.
Journal: Diabetes Metab Syndr (2012): 224
Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes
Authors: Wan HX, Shen JK.
Journal: Yao Xue Xue Bao (2012): 716
Hepatic expression and cellular distribution of the glucose transporter family
Authors: Karim S, Adams DH, Lalor PF.
Journal: World J Gastroenterol (2012): 6771
Endocytosis, recycling, and regulated exocytosis of glucose transporter 4
Authors: Foley K, Boguslavsky S, Klip A.
Journal: Biochemistry (2011): 3048
Sodium-dependent glucose transporter protein as a potential therapeutic target for improving glycemic control in diabetes
Authors: Castaneda-Sceppa C, Castaneda F.
Journal: Nutr Rev (2011): 720